Oncogene:核受体HNF4α在前列腺癌中是一个肿瘤抑制子

2019-11-22 AlexYang MedSci原创

肝细胞的核因子4α(HNF4α, NR2A1)是核受体超家族的一个保守成员。之前的研究阐释了它是一个关键的基因转录调控因子,并广泛的参与异型生物质和药物代谢,并与胃肠道癌症有关。然而,HNF4α在前列腺癌发展过程中的准确功能作用仍旧没有很好的阐释。最近,有研究人员确定了HNF4α在前列腺癌中的功能意义。他们的结果表明,HNF4α在临床前列腺癌组织、前列腺癌细胞系和去势复发前列腺癌异种种植模型中表达

肝细胞的核因子4α(HNF4α, NR2A1)是核受体超家族的一个保守成员。之前的研究阐释了它是一个关键的基因转录调控因子,并广泛的参与异型生物质和药物代谢,并与肠道癌症有关。然而,HNF4α在前列腺癌发展过程中的准确功能作用仍旧没有很好的阐释。

最近,有研究人员确定了HNF4α在前列腺癌中的功能意义。他们的结果表明,HNF4α在临床前列腺癌组织、前列腺癌细胞系和去势复发前列腺癌异种种植模型中表达减少。在前列腺癌细胞中,稳定的HNF4α敲除不仅能够促进细胞增殖而且能够抑制阿霉素(Dox)诱导的细胞衰老和产生紫杉醇治疗抗性,并增强克隆形成能力和前列腺癌细胞体内肿瘤的形成。相反,HNF4α的异位过表达能够显著的抑制前列腺癌细胞的细胞增殖,诱导细胞周期G2/M期阻滞和直接反式激活CDKN1A激活p21信号途径来激发前列腺癌细胞的细胞衰老,并且是p53依赖的方式。

最后,研究人员指出,他们的结果表明了前列腺癌中,HNF4α通过p21驱使的细胞衰老扮演者一个肿瘤抑制子的角色。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677276, encodeId=33fd16e7276a2, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Sat May 02 21:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049253, encodeId=69ef2049253eb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 10 18:09:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809164, encodeId=a6701809164a6, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Jul 16 06:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558171, encodeId=fd7415581e19f, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Nov 24 03:09:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040597, encodeId=8c81104059e58, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Nov 22 15:09:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-05-02 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677276, encodeId=33fd16e7276a2, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Sat May 02 21:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049253, encodeId=69ef2049253eb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 10 18:09:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809164, encodeId=a6701809164a6, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Jul 16 06:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558171, encodeId=fd7415581e19f, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Nov 24 03:09:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040597, encodeId=8c81104059e58, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Nov 22 15:09:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-07-10 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677276, encodeId=33fd16e7276a2, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Sat May 02 21:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049253, encodeId=69ef2049253eb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 10 18:09:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809164, encodeId=a6701809164a6, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Jul 16 06:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558171, encodeId=fd7415581e19f, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Nov 24 03:09:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040597, encodeId=8c81104059e58, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Nov 22 15:09:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677276, encodeId=33fd16e7276a2, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Sat May 02 21:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049253, encodeId=69ef2049253eb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 10 18:09:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809164, encodeId=a6701809164a6, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Jul 16 06:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558171, encodeId=fd7415581e19f, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Nov 24 03:09:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040597, encodeId=8c81104059e58, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Nov 22 15:09:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-24 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677276, encodeId=33fd16e7276a2, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Sat May 02 21:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049253, encodeId=69ef2049253eb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 10 18:09:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809164, encodeId=a6701809164a6, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Jul 16 06:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558171, encodeId=fd7415581e19f, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Nov 24 03:09:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040597, encodeId=8c81104059e58, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Nov 22 15:09:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:前列腺癌中磷脂酶D2随格林森得分蛋白表达变化研究

磷脂酶D1和D2(PLD1/2)在肿瘤发生过程中具有作用,具体是通过产生脂质磷脂酸信号和下游效应来实现。PDL1的抑制能够阻断前列腺细胞的生长和克隆的形成。最近,有研究人员调查了PLD2在前列腺癌中的作用。研究发现,PLD2蛋白在管腔和基底前列腺上皮细胞中基本等量表达。在来自于不同格林森得分的的PCa组织细胞中,PLD2蛋白表达普遍比非肿瘤组织细胞更高,并且在格林森6-8评分的PCa组织中表达增加

Prostate Cancer P D:阿比特龙和恩杂鲁胺治疗相关的副作用事件分析

当新的治疗方法应用于现实情况中时,来源于临床试验的数据并不是都能够提供充分的信息来判断这些治疗方法的影响情况。最近,有研究人员分析了现实使用中与恩杂鲁胺(ENZ)和阿比特龙(ABI)相关的副作用事件情况。在EudraVigilance (EV)数据库中,研究人员鉴定了13562个ABI治疗个体案例和40599个ENZ治疗个体案例。两种药物产生的副作用事件(AEs)中,超过90%的确定为严重AEs。

Oncogene:DEPTOR是一个肿瘤抑制子且能够抑制前列腺致瘤过程

DEPTOR-mTORC1/2途径在细胞培养条件下对各类癌症细胞的增殖调控和生存具有重要的作用,但是依赖于环境。DEPTOR在致瘤过程中的体内作用仍旧不清楚。最近,有研究人员表明了DEPTOR的蛋白水平和mRNA水平在人类前列腺癌组织中大幅度减少,且与疾病的恶化呈现正相关关系。DEPTOR的缺失能够加速人类前列腺癌细胞的增殖、生存、迁移和浸润。同时,DEPTOR的缺失不仅能够激活mTORC1和mT

Prostate Cancer P D:接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究

在晚期癌症患者中使用住院病人姑息治疗(IPC)是较为完善的指南建议。之前的分析阐释了泌尿生殖系(GU)癌症患者在4个检查的原发性癌症(肺癌、乳腺癌、结直肠癌和GU)患者中受益于IPC的比例为排序第3。基于这些结果,研究人员在接受重症监护治疗(CCT)的转移前列腺癌(mPCa)患者中调查了IPC使用的当前趋势和预测因子。研究发现,在接受CCT治疗的4168名mPCa患者中,449名(11.3%)进行

Cell Death & Disease:caveolin-1在前列腺癌进展过程中对旁分泌诱导的研究

一类癌症干细胞(CSCs)亚群在癌症进展、复发和治疗抗性中具有重要的作用。许多研究表明了去势抵抗性前列腺啊(CRPC)与干细胞的表型相关,这些干细胞能够进一步促进神经内分泌转分化。尽管在每种器官中只有一小部分基因预编程细胞具有干细胞能力,CSCs在遗传异质性癌症细胞群体中可能是能够诱导的。然而,导致这些CSCs出现的诱导机制在CRPC中仍旧没有完全清楚。肿瘤细胞能够产生、释放和使用外泌体来促进癌症

Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功

Myovant宣布了其III期HERO研究的阳性结果,该研究对晚期前列腺癌患者中评价了每日一次口服relugolix的疗效。在该数据的支持下,该公司将于2020年第二季度向美国食品和药物管理局(FDA)提交新药申请(NDA)。